Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cryoport, Inc. (CYRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
45.50-0.28 (-0.61%)
At close: 04:00PM EST
45.50 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Sign in to post a message.
  • r
    reed
    The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
  • R
    Russ
    are we done?
    Bullish
  • F
    FossilPoweredPollutingVehicle
    Shouldn't $CYRX go up today?
  • R
    Russ
    Well earnings are here slight profit
    and $85 on the way to $100 by years end IMHO
  • r
    reed
    "Our Biopharma/Pharma revenue increased 371% year over year in the third quarter of 2021 or 41%, organically. But the story does not end there, we now support a record 582 clinical trials, compared with 561 at the end of the second quarter of 2021 and 517 at the end of the third quarter of 2020. We also support eight commercial therapies in regenerative medicine, including Novartis' KYMRIAH®, Gilead/Kite's YESCARTA® and TECARTUS®, bluebird bio's ZYNTEGLO™ and SKYSONA™, Bristol Myers Squibb's BREYANZI® and ABECMA® and Orchard Therapeutics' LIBMELDY™. Additionally, four of the approved therapies received extended or supplemental approvals in the third quarter.
    Bullish
  • r
    reed
    CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, biopharmaceutical and cell and gene therapy markets, headquartered in Paris, France has been recognized as winner of the award, 'The Company You Need to Watch Out For in 2022' at the Europe Bioprocessing Excellence Awards 2021. The virtual awards ceremony held in conjunction with the Biologics Contract Manufacturing Europe 2021 and 4(th) Biologics World Nordic 2021 on October 28, 2021 was attended by over 800 guests representing more than 150 organizations within Europe across 30 different biological product manufacturing categories.
  • R
    Russ
    Jeffries upgrade from 75 to 96
    Bullish
  • R
    Russ
    David you are correct my bad
    I was guessing before reading
  • n
    nito
    COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and Freezing Systems

    OREM, Utah, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced a patent has been granted by the United States Patent Office for an ultracold shipping and storage container for transportation by air that uses liquid nitrogen technology for cooling.

    The large state-of-the-art shipping system could carry many thousands of doses of vaccines and utilizes the commercially proven Cryometrix patented cooling and freezing technology that has the flexibility to provide precise temperature control across a wide range of temperatures. The system accommodates payloads ranging from those requiring conventional refrigeration to specialty products such as COVID-19 and related vaccines that may require temperatures as low as -80° centigrade (-112° Fahrenheit). Systems can be configured to provide for short or long duration shipping cycles, making it an ideal choice for cold chain management.

    Mr. Kim Boyce, CEO of Reflect Scientific, remarked, “Reflect Scientific is now working with organizations such as the governments’ Operation Warp Speed and air carriers that have the expertise to utilize this storage system for specific customized applications.”

    About Reflect Scientific, Inc.

    Reflect Scientific, Inc., based in Orem, Utah, the company develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific’s products are low-temperature freezers and refrigerated systems for laboratory, transportation, and computer server room uses. Visit www.reflectscientific.com for more information. See us on Twitter @ReflectSci and LinkedIn www.linkedin.com/company/reflect-scientific.

    CYRX should just acquire RSCF while its cheap!
  • T
    Techfan20
    Cryoport distributes Mesoblast's stromal cell treatments. $MESO (msb on asx) will soon validate that it can save lives of those with the worst cases of covid19 ARDS. Glad to know the cold supply chain is ready. FDA is scheduled to vote on Mesoblast's remestemcel-l for aGVHD by Sept 30. After Phase 3 read out, remestemcel-l is likely to be extended for severe covid19 ARDS. Lonza already in place to manufacture. Have that cold logistics ready! A robust pipeline of additional products to follow for treatment of other unmet medical needs.
  • L
    LuckyVolatility
    For those of you who are struggling to understand why this company is not just "going to the moon" on news of COVID vaccines requiring cold storage, here are some things to consider.

    1) Cold storage is a very expensive business to maintain. Think about the cost of running a permanent freezer indefinitely. It's like a reverse energy power plant. A single day of a broken freezer means an entire day of hugely unhappy customers. Long term investors will shy away from such risky ventures when so much more opportunity is out there, unless it is some sort of "prime real estate" play as well.

    2) Typical traders that make huge fluctuations are trading on news. News about Pfizer doesn't necessarily mean news about Cryoport. Cryoport had a contract with McKesson for distribution of vaccines, but the Pfizer news doesn't really highlight Cryoport.

    3) Most average short term investors probably don't understand the huge significance freezer transportation has in America. Throughout early days of America, it's biggest strength that helped it flourish was domestic logistics and communication. So without realizing the huge impact either a loss of a company like Cryoport would have, or the huge significance Cryoport has in the supply chain, people won't be as enticed. It's a critical business, but one that often sits in the shadow's of awareness. And its a double edged sword. Only when cold storage messes up really bad will we become aware of the value. But a company with "no bad news" is often good news - so the gen pop doesn't realize that.

    So what does leave? A great and important "behind the scenes business" that happens to benefit from a boost from vaccines that will demand the use of the business. But beyond the near term demand, combined with news of other companies not requiring such intense cold storage, means a company that will probably be only slightly more valued prior to it's "covid19 price" with slow growth over time due to major business changes, and not because of COVID. Probably a safe and necessary buy and hold stock, but not one that will arouse heavy speculative trading. And it is too reliant on certain news being printed.
  • R
    Russ
    what am I missing?
  • S
    Sniff&Rise
    Pfizer demonstrated the vaccine hurray. Next step is how to get them to people whe. the vaccine requires storage at -80 degrees celsius.
    Is there a company that can provide national level cryogenic logistics for more than 300 million doses of vaccine?
    Hmm I wonder where that company could be?😀
  • r
    robert
    CYRX shorts probably like to argue for negative net income and negative free cash flow. However both of those situations are temporary. The positives are a 53 percent gross margin, almost no debt, and net cash more than adequate to pay down the debt. Bottom line, there is more to like here than dislike and the company is on extremely fertile soil for growth now.
  • A
    Ashley
    Cryoport CEO talks distribution, cold-storage services for coronavirus vaccines - December 21, 2020, 3:58 pm
    https://www.google.com/amp/s/finance.yahoo.com/amphtml/video/cryoport-provides-distribution-cold-storage-205827192.html
  • b
    bucnation
    great $100M move - huge cash cushion at reasonable price and modest dilution. smart mgmt team.
  • J
    John Jay
    Every stock with a high short interest is down today, probably because the hedge funds are re-shorting them. TD Ameritrade has a list of about 15 restricted stocks like GME and AMC, and they are all down. So this is another concerted effort by shorts to engage in manipulation of their own to take down anyone who may have gone long one of these stocks. And this is not the result of ETF shorting. None of these stocks would be bought as a basket. This is all targeted for shorting manipulation. But we probably won't hear a peep from the SEC about this activity, which has to involve collusion.
  • D
    DueDiligence_101
    I don't think it's competition, that hit piece on seeking alpha along with short attack did it. Virtually no messages on any 'retail' message boards indicates no interest from retail investors. When it reverses, it should strongly, they are still growing with great numbers every quarter. Still a very strong growth company, if you do not need to sell hold on and eventually this will head north again.
  • r
    reed
    Cryoport now services 528 clinical trials, 45% of all Phase 3 regenerative medicine studies, and six launched cell/gene therapies. Those approved therapeutics include high-profile names like Kymriah, Yescarta, Zyntelgo, Tecartus, Breyanzi, and Limeldy.
  • A
    Anonymous
    Folks, this just profit taking. Wait until a couple of Phase III approvals and this will be back near 20.
Advertisement
Advertisement